New psoriatic arthritis data a further boost for Cosentyx

An interleukin (IL)-17 inhibitor from Swiss pharma giant Novartis (NOVN: VX) is not only delivering on the psoriatic arthritis (PsA) market, but also continuing to give promising new results in major studies.

Cosentyx (secukinumab) was only approved by the US Food and Drug Administration (FDA) in 2015, but its popularity with rheumatologists means that it is already taking patient share from established PsA TNF-inhibitors.

Excitement around the drug’s potential will be boosted further by the new data presented at the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting in Washington DC.